TrialStudy to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)
Trial details
- Registry ID
- NCT02501018
- Phase
- Phase 2
LSTA
Lisata Therapeutics, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
7Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)NCT02501018 | LSTA | Phase 2 | Completed | 2022-05-19Actual |
| A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular DysfunctionNCT04614467 | LSTA | Phase 2 | Terminated | 2022-09-28Actual |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsNCT05712356 | LSTA | Phase 2 | Completed | 2026-04-05Actual |
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
Trial details
- Registry ID
- NCT04614467
- Phase
- Phase 2
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Trial details
- Registry ID
- NCT05712356
- Phase
- Phase 2
Latest recorded trial changes
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
NCT05712356 · Lisata Therapeutics, Inc.
Recruitment status changed
− Before
Terminated
+ After
Completed
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
NCT05712356 · Lisata Therapeutics, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Incidence of adverse events
+ After
Measure: Number of Subjects Experiencing Any Adverse Event
Actual enrollment decreased by 1 participants
− Before
67 participants (actual)
+ After
66 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
18 Apr 2026
+ After
5 Apr 2026
Recruitment status changed
− Before
Active not recruiting
+ After
Terminated
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
NCT04614467 · Lisata Therapeutics, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Change From Baseline in Angina Frequency
Measure: Change From Baseline in CCS Angina Class
Measure: Change From Baseline in Total Exercise Time
Measure: Change From Baseline in Health-related Quality of Life (HRQoL)
+ After
Measure: Change From Baseline in Number of Angina Attacks Per Week Measure: Change From Baseline in CCS Angina Class Measure: Change From Baseline in Total Exercise Time Measure: Change From Baseline in Health-related Quality of Life (HRQoL)